UMG:EURONEXT AMSTERDAMUniversal Music Group N.V. Analysis
Data as of 2026-07-08 - not real-time
$21.42
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The share price is trading above its short‑term 20‑day moving average but remains below both the 50‑day and 200‑day averages, indicating a loss of upward momentum. The RSI hovers around the 50‑point midpoint, suggesting neutral pressure, while the MACD histogram is modestly positive yet the overall trend is flagged as bearish and volume is on a downtrend.
Fundamental backdrop: Revenue growth is modest at around 5% with solid gross and operating margins, and ROE exceeds 30%. However, the valuation is stretched – the PE ratio is well above the industry average and the DCF‑derived fair value is far below the current price. A 3% dividend yield is attractive but the payout ratio above 60% combined with a recent €500 million senior note issuance pushes the debt‑to‑equity ratio to a high level, raising sustainability concerns.
Market sentiment and risk: The Fear & Greed index sits in the “Extreme Greed” zone, while 30‑day volatility exceeds 35% and the stock’s beta is below 1, indicating higher price swings with limited market correlation. Historical max drawdown approaching 46% underscores the downside risk despite a strong brand and cash‑flow generation.
Fundamental backdrop: Revenue growth is modest at around 5% with solid gross and operating margins, and ROE exceeds 30%. However, the valuation is stretched – the PE ratio is well above the industry average and the DCF‑derived fair value is far below the current price. A 3% dividend yield is attractive but the payout ratio above 60% combined with a recent €500 million senior note issuance pushes the debt‑to‑equity ratio to a high level, raising sustainability concerns.
Market sentiment and risk: The Fear & Greed index sits in the “Extreme Greed” zone, while 30‑day volatility exceeds 35% and the stock’s beta is below 1, indicating higher price swings with limited market correlation. Historical max drawdown approaching 46% underscores the downside risk despite a strong brand and cash‑flow generation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near resistance with decreasing volume
- Technical indicators showing mixed but overall bearish bias
- Elevated valuation relative to peers
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong cash flow and high ROE supporting earnings stability
- High leverage after recent debt issuance
- Dividend yield attractive but payout ratio raises sustainability questions
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust brand and diversified music‑rights portfolio
- Persistent overvaluation versus DCF fair value
- Potential for improved capital structure if earnings growth accelerates
Key Metrics & Analysis
Financial Health
Revenue Growth5.00%
Profit Margin12.26%
P/E Ratio22.8
ROE33.78%
ROA7.67%
Debt/Equity74.58
P/B Ratio7.5
Op. Cash Flow$1.7B
Free Cash Flow$1.6B
Industry P/E16.1
Technical Analysis
TrendBearish
RSI50.6
Support$20.10
Resistance$21.97
MA 20$20.93
MA 50$21.97
MA 200$23.92
MACDBullish
VolumeDecreasing
Fear & Greed Index89.07
Valuation
Fair Value$12.26
GradeOvervalued
TypeBlend
Dividend Yield3.03%
Risk Assessment
Beta0.79
Volatility35.04%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.